Go Pro
NASDAQ:NAGE

Niagen Bioscience Q1 2026 Earnings Report

Niagen Bioscience logo
$3.04 +0.05 (+1.67%)
Closing price 09/21/2026 04:00 PM Eastern
Extended Trading
$3.04 0.00 (0.00%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Niagen Bioscience EPS Results

Actual EPS
$0.07
Consensus EPS
$0.06
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Niagen Bioscience Revenue Results

Actual Revenue
$31.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Niagen Bioscience Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Niagen Bioscience Earnings Headlines

Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11.tc pixel
Niagen Bioscience, Inc. (NAGE)
See More Niagen Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email.

About Niagen Bioscience

Niagen Bioscience (NASDAQ:NAGE) is a bioscience company focused on developing and commercializing products designed to support healthy aging and cellular energy metabolism. The company’s research centers on nicotinamide riboside (NR), a form of vitamin B3 and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in numerous cellular processes.

The company markets its proprietary NIAGEN branded NR ingredient to supplement manufacturers and sells consumer products under the Tru Niagen brand. Tru Niagen products are available in dietary supplement formulations intended to support NAD+ levels and cellular health. Niagen Bioscience also maintains intellectual property and conducts research related to NR and NAD+ biology.

The company was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name as part of its focus on the NIAGEN platform. Its products are marketed through direct-to-consumer and commercial channels in the United States and internationally. The company is led by Chief Executive Officer Robert N. Fried.

View Niagen Bioscience Profile